Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare Biotechnology
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire May 10, 2024

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

PR Newswire March 28, 2024

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

PR Newswire January 8, 2024

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire November 9, 2023

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

PR Newswire September 19, 2023

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

PR Newswire August 23, 2023

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire August 10, 2023

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

PR Newswire July 11, 2023

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

PR Newswire June 15, 2023

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

PR Newswire May 24, 2023

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire May 12, 2023

Pulmatrix Supports World Asthma Day 2023

PR Newswire May 2, 2023

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

PR Newswire March 30, 2023

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

PR Newswire February 6, 2023

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

PR Newswire January 25, 2023

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

PR Newswire January 23, 2023

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

PR Newswire January 4, 2023

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire November 10, 2022

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

PR Newswire September 26, 2022

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 8, 2022